Tag: Apalutamide

Neoadjuvant hormonal therapy promising in high-risk prostate cancer

Presented By
Prof. Steven Joniau, UZ Leuven, Belgium
Trial
Phase 2, ARNEO
Conference
EAU 2022
Type
News article

22 July 2022 12:35

Best of EAU: Updates on imaging and treatment of prostate cancer

Presented By
Prof. Alberto Briganti, IRCCS Ospedale San Raffaele, Milan, Italy
Trial
STHLM3MRI, TITAN
Conference
EAU 2021
Type
Peer-reviewed article

31 August 2021 12:15

Apalutamide prolongs progression-free survival in prostate cancer

Presented By
Dr Dana Rathkopf, Memorial Sloan Kettering Cancer Center, New York, USA
Trial
Phase 3, ACIS
Conference
ASCO GU 2021
Type
Peer-reviewed article

24 March 2021 14:49

Intrinsic tumour biology may be predictive of treatment response in prostate cancer

Presented By
Prof. Felix Feng, University of California San Francisco, USA
Trial
Phase 3, SPARTAN
Conference
ASCO GU 2021
Type
Peer-reviewed article

24 March 2021 14:46

Final TITAN trial results favour use of apalutamide

Presented By
Dr Kim Chi, British Columbia Cancer and Vancouver Prostate Centre, Canada
Trial
Phase 3, TITAN
Conference
ASCO GU 2021
Type
Peer-reviewed article

24 March 2021 14:46

ARAMIS final OS and nmCRPC safety outcomes

Expert
Prof. Karim Fizazi, Institut Gustave Roussy, France
Trial
Phase 3, ARAMIS
Conference
ASCO 2020
Type
Peer-reviewed article

17 September 2020 14:11

Final survival results from phase 3 SPARTAN trial

Expert
Prof. Eric J. Small, University of California San Francisco, CA, USA
Trial
Phase 3, SPARTAN
Conference
ASCO 2020

17 September 2020 14:01

25% reduction in the risk of death in patients with nmCRPC treated with apalutamide

Presented By
Prof. Matthew Smith, Massachusetts General Hospital, Boston, USA
Trial
Phase 3, SPARTAN
Conference
ESMO 2019
Type
Peer-reviewed article

26 November 2019 23:23

Enzalutamide offers survival advantage over other NSAAs in mHSPC

Presented By
Dr Christopher Sweeney, Dana-Farber Cancer Institute, USA
Trial
ENZAMET, TITAN
Conference
ASCO 2019
Type
Peer-reviewed article

15 July 2019 23:26

Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer

Presented By
Dr Kim N. Chi, BC Cancer Agency, Canada
Trial
Phase 3, TITAN
Conference
ASCO 2019
Type
Peer-reviewed article

15 July 2019 22:28
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com